Novel Inactivated Virus Vaccine Against Herpesviruses
Prophylactic and therapeutic vaccines against herpesviruses associated diseases.
Researchers at the University of California have developed a new and very effective method of vaccination against HSV2. The vaccine consists of a combination of inactivated herpesvirus mixed with the adjuvants monophosphoryl lipid A (MPL) and alum. The invention has been proved in animal models to afford complete protection against acute and recurrent HSV-2 genital diseases, and provided significantly higher levels of protection against both disease and virus shedding compared with another vaccine now in clinical trials.
Inventor: SPECTOR, Deborah, H. | MORELLO, Christopher, S. | KRAYNYAK, Kimberly, A.
Priority Number: WO2013006569A3
IPC Current: A61K0039245 | A61K0009127 | A61K003939 | A61K004748 | A61P002528 | A61P003100
Assignee Applicant: The Regents of the University of California
Title: HERPES VIRUS VACCINE AND METHODS OF USE | VACCIN CONTRE LE VIRUS DE L'HERPÈS ET PROCÉDÉS D'UTILISATION
Usefulness: HERPES VIRUS VACCINE AND METHODS OF USE | VACCIN CONTRE LE VIRUS DE L'HERPÈS ET PROCÉDÉS D'UTILISATION
Summary: The agent is useful for treating disease caused by HV infection. The disease is chosen from herpetic gingivostomatitis, herpes labialis, herpes genitalis, herpetic whitlow, herpes gladiatorum, herpesviral encephalitis, herpesviral meningitis, herpes esophagitis, herpes keratitis, Bell's palsy, Mollaret's meningitis, herpes rugbeiorum, eczema herpeticum, herpetic neuralgia, post-herpetic neuralgia and Alzheimer's disease (all claimed).
Novelty: Vaccine useful for treating disease e.g. herpetic gingivostomatitis and herpes labialis caused by herpes virus infection, comprises inactivated HV, lipopolysaccharide-derived adjuvant and aluminum-based mineral salt adjuvant
Biomedical
Pharmaceuticals
9555100
State Of Development Inventors have validated the novel vaccine in vivo, using mouse and guinea pig models. The vaccine was able to completely protect against both acute and recurrent lesion development, and to clear the virus from the dorsal root ganglia. Ongoing studies show that further modifications to the technique produce even greater therapeutic efficacy. Intellectual Property Info Worldwide rights are available. Publication # WO 2013/006569 A2, Application # PCT/US2012/045290 For background information please also see case number 2006-121. Related Materials Morello CS, et. al., Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine. 2012 Oct 12;30(46): 6541-50. Additional Technologies by these Inventors Tech ID/UC Case 22936/2011-325-0 Related Cases 2011-325-0
Morello CS, et al., Immunization with Herpes Simplex Virus 2 (HSV-2) Genes plus Inactivated HSV-2 Is Highly Protective against Acute and Recurrent HSV-2 Disease. J Virol. (2011) 85(7): 3461-72.
USA
